Thyroid cancer Drug's side effect on body mass measured in small study
NCT ID NCT07543887
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study from the University of Pisa looked at how the thyroid cancer drug selpercatinib affects body composition. Fifteen adults on the drug had their lean mass and energy expenditure measured. The goal was simply to observe and gather data, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selpercatinib
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Pisa
Pisa, PI, 56124, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic test may spare patients from unnecessary thyroid surgery
- Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
- Can an immune booster make radioiodine more effective against thyroid cancer?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can math make thyroid hormone therapy more precise?
- Can AI help surgeons see thyroid cancer more clearly?